News February 19, 2021 Daniela Salvemini named to Chair of Pharmacology and Physiology IDBI Member and distinguished scientist, Daniela Salvemini, has accepted the position of William Beaumont Professor and Chair of the Department […]
Recent publications July 3, 2020 IDBI Member’s Research Selected for Editor’s Pick in the Journal for Biological Chemistry A research article from Dr. Jinsong Zhang’s lab, entitled “The transcriptional corepressor CBFA2T3 inhibits all-trans-retinoic acid–induced myeloid gene expression and […]
News May 18, 2020 IDBI Member Leads SLU’s COVID-19 Treatment Trial Clinical Trial for experimental drug remdesivir, under the direction of IDBI member Dr.Sarah George, shows promising results for the reduction […]
News July 12, 2020 IDBI Member co-founder of new company John Walker is a part-founder in a new company, as of July 2020, that has been formed called Myonid Therapeutics. The […]
Recent publications July 3, 2020 Probing the Structure-Function Relationship of Hemoglobin in Living Human Red Blood Cells Researchers from the lab of Piotr Mak studying the structure and function of hemoglobin was published in Spectrochimica Acta Part A: […]
News May 29, 2020 Watch IDBI Members Present Research on COVID-19 Research IDBI members, John Tavis, Ph.D. and Amelia Pinto, Ph.D., presented their research on “Challenges of Drug Development During the COVID-19 […]
News May 29, 2019 SLU Researchers Flip Pain Switch in Spinal Cord Cells In findings published in Proceedings of the National Academy of Sciences (PNAS), Saint Louis University scientists and their colleagues report progress on […]
Recent publications May 28, 2019 Novel anti-malarial agents IDBI member Marvin Meyers recently published a study on the identification of novel chemotypes with antimalarial efficacy to combat the […]
Recent publications May 28, 2019 New therapies for kidney fibrosis? David Griggs published a review on the therapeutic possibilities of targeting TGF-beta to treat kidney fibrosis. It was published in […]
Recent publications May 28, 2019 HBV RNaseH as a promising antiviral target The Tavis lab makes the case for the Hepatitis B virus RNaseH as a very promising target for new inhibitors […]
